rawfin.tv
Celcuity Targets July 17 FDA Decision for Gedatolisib, Expands VIKTORIA-2 Study
MarketsstocksAI Generated

Celcuity Targets July 17 FDA Decision for Gedatolisib, Expands VIKTORIA-2 Study

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Celcuity is awaiting a July 17 FDA decision for its drug gedatolisib, a key milestone for the company's pipeline. Concurrently, the biotech firm is expanding its VIKTORIA-2 study, signaling ongoing development efforts.

biotechdrug developmentFDA approvalclinical trialshealthcare

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks